Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

South Korea flag South Korea · Delayed Price · Currency is KRW
63,300
+1,500 (2.43%)
Jun 2, 2026, 3:30 PM KST
Market Cap1.92T +68.7%
Revenue (ttm)7.97B -8.2%
Net Income-36.93B
EPS-1,223.48
Shares Out 30.39M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume268,096
Open60,800
Previous Close61,800
Day's Range59,100 - 64,000
52-Week Range35,850 - 179,900
Beta1.30
Analystsn/a
Price Targetn/a
Earnings DateApr 3, 2026

About Mezzion Pharma

Mezzion Pharma Co.,Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company developing JURVIGO, which is in Phase 3 clinical trial for treatment option to improve the physiology and exercise capacity of Fontan patients 12 years and older. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is headquartered in Seoul, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2002
Employees 18
Stock Exchange KOSDAQ
Ticker Symbol 140410
Full Company Profile

Financial Performance

In 2025, Mezzion Pharma's revenue was 7.91 billion, a decrease of -8.15% compared to the previous year's 8.61 billion. Losses were -34.93 billion, 79.3% more than in 2024.

Financial Statements